Endo Pharma, Penwest Settle Opana ER Patent Litigation With Sandoz

Under the terms of the settlement, Endo and Penwest have agreed to grant Sandoz a license to sell a generic of Opana ER on September 15, 2012.

Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system.

Endo Pharmaceuticals is a specialty pharmaceutical company engaged in the research, development, sale and marketing of branded and generic prescription pharmaceuticals used to treat and manage pain, prostate cancer and the early onset of puberty in children, or central precocious puberty (CPP).